TheEdgeResearch
Home / Stocks / OKUR

OnKure Therapeutics, Inc. (OKUR)

NASDAQ Healthcare Biotechnology
$2.70 ▼ -2.17%
Market Cap
$109.4M
Sector
Healthcare
Industry
Biotechnology
Beta
0.30
52-Wk Range
2.01-5.38
CEO
Nicholas A. Saccomano
Country
US
Currency
USD

OnKure Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Boulder, CO, US. The stock last traded at $2.70, down 2.17% on the session, giving a market capitalisation of $109.4M. On trailing twelve-month figures it carries a trailing P/E of -0.97, a net margin of 0.0%. Its beta of 0.30 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.97
Price / Sales
0.00
Price / Book
0.85
EV / EBITDA
0.68
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.01
Current ratio
18.84
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
45
IPO date
2021-04-08
Headquarters
Boulder, CO, US
About OnKure Therapeutics, Inc.

OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.

Comparable companies

OnKure Therapeutics, Inc. is most often compared with the following Healthcare names:

ALGSATNMBRNSCVMFGENKZRMRSNPDSBTPSTXLO
More research on OKUR
OKUR technical analysis OKUR TheEdge Score Compare against peers
Open full interactive analysis & DCF →